Safety, Tolerability, and Patient Counseling in Combination Therapy

In this episode, Dr. Yu and Dr. Puri address the safety profile of combination regimens and how to counsel patients. In TOP, grade 3 or higher treatment-related adverse events (TRAEs) occurred in 62% of the combination arm versus 14.9% with monotherapy, driven by neutropenia, anemia, and thrombocytopenia. Dr. Puri describes osimertinib plus chemotherapy adverse events (AEs) as predominantly cytopenias that rarely become clinically significant — febrile neutropenia and bleeding events are uncommon — and are manageable with standard dose modifications. With amivantamab/lazertinib, the toxicity profile shifts to cutaneous, nail, and thromboembolic events, requiring upfront prophylaxis, infusion-reaction premedication (lessened by subcutaneous formulation), and proactive dermatology referral, particularly in sun-exposed regions like Florida. Dr. Yu emphasizes that amivantamab/lazertinib demands committed patients who will follow through with twice-daily moisturizing, nail care, and anticoagulation. They discuss community vs academic settings: Community oncologists may have less lung-specific experience but bring familiarity with related toxicity patterns from cetuximab and similar agents; the key is building a structured workflow rather than reacting to events. On practical thresholds, Dr. Puri dose-reduces by 25% for absolute neutrophil count (ANC) under 500 or platelets under 50,000, with greater reductions for clinically significant bleeding, and uses granulocyte colony-stimulating factor (G-CSF) after the first event of significant neutropenia rather than as primary prophylaxis. Dr. Yu agrees, adding that pemetrexed maintenance has cumulative toxicity and a low threshold to stop is appropriate.

In the next episode, “Sequencing After First-Line Combination Therapy,” Dr. Puri and Dr. Yu walk through second-line options at progression.